Characteristics and Outcomes of Complicated Intra-abdominal Infections Involving Pseudomonas aeruginosa from a Randomized, Double-Blind, Phase 3 Ceftolozane-Tazobactam Study-Reference-Cited by-同舟云学术

Characteristics and Outcomes of Complicated Intra-abdominal Infections Involving Pseudomonas aeruginosa from a Randomized, Double-Blind, Phase 3 Ceftolozane-Tazobactam Study

Published:2016-07 Issue:7 Volume:60 Page:4387-4390
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Miller Benjamin¹,Popejoy Myra W.²,Hershberger Ellie²,Steenbergen Judith N.²,Alverdy John³

Affiliation:

1. Department of Medical Affairs, Merck & Co., Inc., Kenilworth, New Jersey, USA

2. Merck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey, USA

3. Department of Surgery, University of Chicago Medical Center, Chicago, Illinois, USA

Abstract

ABSTRACT Ceftolozane-tazobactam is active against Gram-negative pathogens, including multidrug-resistant Pseudomonas aeruginosa . In a subgroup analysis of patients with complicated intra-abdominal infections (cIAIs) involving P. aeruginosa from a phase 3 program, ceftolozane-tazobactam demonstrated potent in vitro activity against P. aeruginosa . Clinical cure in the microbiologically evaluable population was 100% (26/26) for ceftolozane-tazobactam plus metronidazole and 93.1% (27/29) for meropenem. These findings support the use of ceftolozane-tazobactam in the management of cIAI when P. aeruginosa is suspected or confirmed. (This study has been registered at ClinicalTrials.gov under registration no. NCT01445665 and NCT01445678.)

Funder

Merck

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.03074-15

Reference20 articles.

1. Complicated intra-abdominal infections worldwide: the definitive data of the CIAOW Study

2. Center for Disease Dynamics Economics & Policy. 2013. ResistanceMap database: The Surveillance Network. USA Center for Disease Dynamics, Economics & Policy, Washington, DC. http://www.cddep.org/map. Accessed 17 March 2016.

3. European Centre for Disease Prevention and Control. 2013. Antimicrobial resistance surveillance in Europe 2013. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-surveillance-europe-2013.pdf. Accessed 17 March 2016.

4. Merck & Co., Inc. 2015. Zerbaxa prescribing information. Merck & Co., Inc., Whitehouse Station, NJ.

5. Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination with Tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis Strains Having Various Resistance Phenotypes

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of novel β-lactams for Pseudomonas aeruginosa infection: A systematic review and meta-analysis;American Journal of Infection Control;2024-07

2. Extensively drug-resistant Pseudomonas aeruginosa: clinical features and treatment with ceftazidime/avibactam and ceftolozane/tazobactam in a tertiary care university hospital center in Portugal – A cross-sectional and retrospective observational study;Frontiers in Microbiology;2024-02-13

3. Perspectives on the use of ceftolozane/tazobactam: a review of clinical trial data and real-world evidence;Future Microbiology;2024-01-22

4. Efficacy and safety of tazobactam/ceftolozane in combination with metronidazole for intraabdominal infection in a hepato-biliary-pancreatic field in clinical practice;Journal of Infection and Chemotherapy;2023-09

5. Efficacy of co-loading Ag nanoparticles and metronidazole in PEG–gelatin-based sponges for the treatment of chronic wounds;Polymer Bulletin;2023-08-07